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Background: Optimizing the effect on HbA1c while avoiding weight gain and edema are keys to successful thiazolidinedione therapy. Previously we 
identified physiogenomic associations of SNPs in ADORA1 to weight gain and NPY to edema (Ruaño et al., Clin Chim Acta 400:48-55, 2009). Here we 
apply physiogenomic analysis to HbA1c lowering.
Methods: 87 outpatients treated with pioglitazone or rosiglitazone at a Joslin Center Clinic (New Britain, CT) were characterized for HbA1c 
in addition to body mass index (BMI), and presence/absence of edema. We genotyped 347 SNPs (single nucleotide polymorphism) from our 
PhysioGenomic (PG) Array of 222 cardiometabolic and neuroendocrine genes.
Results: We discovered significant associations between the efficacy phenotype HbA1c and SNPs in five genes, of which the strongest association 
was to rs706713 in the gene PIK3R1 (phosphatidylinositol 3-kinase, regulatory subunit 1, p<0.001), a haplotype tagging synonymous SNP located in 
exon 1. Other associations were to ACACA (acetyl-Coenzyme A carboxylase alpha) rs8081866 (p<0.012), GNAO1 (G protein, alpha activating activity 
polypeptide-O rs4784642 (p<0.013), EDN1 (endothelin 1) rs5369 (p<0.014), and INSR (insulin receptor) rs4804103 (p<0.016), none of which 
were linked to BMI or edema. UCP3 (uncoupling protein 3) was moderately associated to both HbA1c and BMI.
Conclusions: We have found additional evidence supporting thiazolidinedione response phenotypes being modulated by separate pathways. The 
findings permit the construction of a safety/efficacy model that combines BMI, edema, and HbA1c reduction components. Pending further validation, 
we predict that such models can help clinicians minimize side effects and maximize efficacy in prescribing thiazolidinediones.
